The proposed guideline will replace ‘points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome CPMP/EWP/785/97’. Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder in which abdominal discomfort or pain is associated with changes in bowel habits, stool consistency and other features of disordered defecation.
| Consultation start date | 08/06/2012 |
|---|---|
| Consultation end date | 31/08/2012 |
| Email address for submissions | gastroenterologydg@ema.europa.eu |